{
    "clinical_study": {
        "@rank": "168083", 
        "acronym": "EVOLVE II QCA", 
        "arm_group": {
            "arm_group_label": "SYNERGY Stent System", 
            "arm_group_type": "Experimental", 
            "description": "SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System (SYNERGY Stent System)"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate 9 month angiographic and intravascular ultrasound\n      (IVUS) data for the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System\n      (SYNERGY Stent System) in the treatment of subjects with atherosclerotic lesion(s) \u226434 mm in\n      length (by visual estimate) in native coronary arteries \u22652.25 mm to \u22644.0 mm in diameter (by\n      visual estimate)."
        }, 
        "brief_title": "EVOLVE II QCA: A Prospective, Multicenter Trial to Assess the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System (SYNERGY Stent System) for the Treatment of Atherosclerotic Lesion(s)", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Atherosclerotic Lesion(s)", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subject must be at least 18 years of age\n\n          -  Subject (or legal guardian) understands the trial requirements and the treatment\n             procedures and provides written informed consent before any trial-specific tests or\n             procedures are performed\n\n          -  For subjects less than 20 years of age enrolled at a Japanese site, the subject and\n             the subject's legal representative must provide written informed consent before any\n             study-specific tests or procedures are performed\n\n          -  Subject is eligible for percutaneous coronary intervention (PCI)\n\n          -  Subject has symptomatic coronary artery disease with objective evidence of ischemia\n             or silent ischemia\n\n          -  Subject is an acceptable candidate for coronary artery bypass grafting (CABG)\n\n          -  Subject is willing to comply with all protocol-required follow-up\n             evaluation\n\n        Angiographic Inclusion Criteria (visual estimate)\n\n          -  Target lesion(s) must be located in a native coronary artery with a visually\n             estimated reference vessel diameter (RVD) \u22652.25 mm and \u22644.0 mm\n\n          -  Target lesion(s) length must be \u226434 mm (by visual estimate)\n\n          -  Target lesion(s) must have visually estimated stenosis \u226550% and <100% with\n             thrombolysis in Myocardial Infarction (TIMI) flow >1 and one of the following\n             (stenosis \u226570%, abnormal fractional flow reserve (FFR), abnormal stress or imaging\n             stress test, or elevated biomarkers prior to the procedure)\n\n          -  Coronary anatomy is likely to allow delivery of a study device to the target\n             lesions(s)\n\n          -  The first lesion treated must be successfully pre-dilated/pretreated\n\n        Exclusion Criteria:\n\n          -  Subject has clinical symptoms and/or electrocardiogram (ECG) changes consistent with\n             acute ST elevation MI (STEMI)\n\n          -  Subject has cardiogenic shock, hemodynamic instability requiring inotropic or\n             mechanical circulatory support, intractable ventricular arrhythmias, or ongoing\n             intractable angina\n\n          -  Subject has received an organ transplant or is on a waiting list for an organ\n             transplant\n\n          -  Subject is receiving or scheduled to receive chemotherapy within 30 days before or\n             after the index procedure\n\n          -  Planned PCI (including staged procedures) or CABG after the index procedure\n\n          -  Subject previously treated at any time with intravascular brachytherapy\n\n          -  Subject has a known allergy to contrast (that cannot be adequately premedicated)\n             and/or the trial stent system or protocol-required concomitant medications (e.g.,\n             platinum, platinum-chromium alloy, stainless steel, everolimus or structurally\n             related compounds, polymer or individual components, all P2Y12 inhibitors\n             (clopidogrel, ticlopidine, prasugrel, or ticagrelor), or aspirin)\n\n          -  Subject has one of the following (as assessed prior to the index procedure):\n\n               -  Other serious medical illness (e.g., cancer, congestive heart failure) with\n                  estimated life expectancy of less than 24 months\n\n               -  Current problems with substance abuse (e.g., alcohol, cocaine, heroin, etc.)\n\n               -  Planned procedure that may cause non-compliance with the protocol or confound\n                  data interpretation\n\n          -  Subject is receiving chronic (\u226572 hours) anticoagulation therapy (i.e., heparin,\n             coumadin) for indications other than acute coronary syndrome\n\n          -  Subject has a platelet count <100,000 cells/mm3 or >700,000 cells/mm3\n\n          -  Subject has a white blood cell (WBC) count < 3,000 cells/mm3\n\n          -  Subject has documented or suspected liver disease, including laboratory evidence of\n             hepatitis\n\n          -  Subject is on dialysis or has baseline serum creatinine level >2.0 mg/dL (177\u00b5mol/L)\n\n          -  Subject has a history of bleeding diathesis or coagulopathy or will refuse blood\n             transfusions\n\n          -  Subject has had a history of cerebrovascular accident (CVA) or transient ischemic\n             attack (TIA) within the past 6 months\n\n          -  Subject has an active peptic ulcer or active gastrointestinal (GI) bleeding\n\n          -  Subject has severe symptomatic heart failure (i.e., New York Heart Association (NYHA)\n             class IV)\n\n          -  Subject is participating in another investigational drug or device clinical trial\n             that has not reached its primary endpoint\n\n          -  Subject intends to participate in another investigational drug or device clinical\n             trial within 12 months after the index procedure\n\n          -  Subject with known intention to procreate within 12 months after the index procedure\n             (women of child-bearing potential who are sexually active must agree to use a\n             reliable method of contraception from the time of screening through 12 months after\n             the index procedure)\n\n          -  Subject is a woman who is pregnant or nursing (a pregnancy test must be performed\n             within 7 days prior to the index procedure in women of child-bearing potential)\n\n        Angiographic Exclusion Criteria (visual estimate)\n\n        Planned treatment of more than 3 lesions\n\n          -  Planned treatment of lesions in more than 2 major epicardial vessels\n\n          -  Planned treatment of a single lesion with more than 1 stent\n\n          -  Subject has 2 target lesions in the same vessel that are separated by less than 15 mm\n             (by visual estimate)\n\n          -  Target lesion(s) is located in the left main\n\n          -  Target lesion(s) is located within 3 mm of the origin of the left anterior descending\n             (LAD) coronary artery or left circumflex (LCx) coronary artery by visual estimate.\n\n          -  Target lesion(s) is located within a saphenous vein graft or an arterial graft\n\n          -  Target lesion(s) will be accessed via a saphenous vein graft or arterial graft\n\n          -  Target lesion(s) with a TIMI flow 0 (total occlusion) or TIMI flow 1 prior  to guide\n             wire crossing\n\n          -  Target lesion(s) treated during the index procedure that involves a complex\n             bifurcation (e.g., bifurcation lesion requiring treatment with more than 1 stent)\n\n          -  Target lesion(s) is restenotic from a previous stent implantation or study stent\n             would overlap with a previous stent\n\n          -  Subject has unprotected left main coronary artery disease (>50% diameter stenosis)\n\n          -  Subject has been treated with any type of PCI (i.e., balloon angioplasty, stent,\n             cutting balloon atherectomy) within 24 hours prior to the index procedure\n\n          -  Thrombus, or possible thrombus, present in the target vessel (by visual estimate)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 16, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01787799", 
            "org_study_id": "S2072"
        }, 
        "intervention": {
            "arm_group_label": "SYNERGY Stent System", 
            "description": "Synergy is a device/drug combination product composed of two components, a device (coronary stent system including a chromium stent platform) and a drug product (a formulation of everolimus contained in a bioabsorbable polymer coating.", 
            "intervention_name": "SYNERGY", 
            "intervention_type": "Device"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Chromium", 
                "Everolimus", 
                "Sirolimus"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Drug-eluting stents", 
        "lastchanged_date": "December 11, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Chermside", 
                        "country": "Australia", 
                        "state": "Queensland", 
                        "zip": "4032"
                    }, 
                    "name": "The Prince Charles Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Clayton", 
                        "country": "Australia", 
                        "state": "Victoria", 
                        "zip": "3168"
                    }, 
                    "name": "Monash Medical Centre-Clayton Campus"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Fitzroy", 
                        "country": "Australia", 
                        "state": "Victoria", 
                        "zip": "3085"
                    }, 
                    "name": "St Vincent's Hospital Melbourne"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Fremantle", 
                        "country": "Australia", 
                        "state": "Western Australia", 
                        "zip": "6160"
                    }, 
                    "name": "Fremantle Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kamakura-shi", 
                        "country": "Japan", 
                        "state": "Kanagawa", 
                        "zip": "247-8533"
                    }, 
                    "name": "Shonan Kamakura General Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Auckland", 
                        "country": "New Zealand", 
                        "zip": "622"
                    }, 
                    "name": "North Shore Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Auckland", 
                        "country": "New Zealand", 
                        "zip": "1640"
                    }, 
                    "name": "Middlemore Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Auckland", 
                        "country": "New Zealand", 
                        "zip": "1050"
                    }, 
                    "name": "Ascot Angiography Ltd"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Auckland", 
                        "country": "New Zealand", 
                        "zip": "1010"
                    }, 
                    "name": "Auckland City Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Auckland", 
                        "country": "New Zealand", 
                        "zip": "1003"
                    }, 
                    "name": "Mercy Angiography Unit, Ltd."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Christchurch", 
                        "country": "New Zealand", 
                        "zip": "8011"
                    }, 
                    "name": "Christchurch Hospital NZ"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Singapore", 
                        "country": "Singapore", 
                        "zip": "168752"
                    }, 
                    "name": "National Heart Centre"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Singapore", 
                        "country": "Singapore", 
                        "zip": "119074"
                    }, 
                    "name": "National University Hospital"
                }
            }
        ], 
        "location_countries": {
            "country": [
                "Australia", 
                "Japan", 
                "New Zealand", 
                "Singapore"
            ]
        }, 
        "number_of_arms": "1", 
        "official_title": "A Prospective, Multicenter Trial to Evaluate 9 Month Angiographic and Intravascular Ultrasound (IVUS) Data for the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System (SYNERGY Stent System) in the Treatment of Subjects With Atherosclerotic Lesion(s) \u226434 mm in Length (by Visual Estimate) in Native Coronary Arteries \u22652.25 mm to \u22644.0 mm in Diameter (by Visual Estimate)", 
        "overall_official": {
            "affiliation": "Monash Medical Centre-Clayton Campus, 246 Clayton Road, 3168 Clayton, Victoria, Australia", 
            "last_name": "Ian Meredith, Professor", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": [
                "Australia: National Health and Medical Research Council", 
                "New Zealand: Ministry of Health", 
                "Singapore: Ministry of Health", 
                "Japan: Pharmaceuticals and Medical Devices Agency"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "In-stent late loss at 9 months post-procedure as measured by quantitative coronary angiography (QCA)", 
            "measure": "In-stent late loss", 
            "safety_issue": "No", 
            "time_frame": "9 month"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01787799"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Target lesion revascularization (TLR) rate", 
                "safety_issue": "Yes", 
                "time_frame": "30 days, 9 months, 12 months"
            }, 
            {
                "measure": "Target lesion failure (TLF) rate", 
                "safety_issue": "Yes", 
                "time_frame": "30 days, 9 months, 12 months"
            }, 
            {
                "measure": "Target vessel revascularization (TVR) rate", 
                "safety_issue": "Yes", 
                "time_frame": "30 days, 9 months, 12 months"
            }, 
            {
                "measure": "Target vessel failure (TVF) rate", 
                "safety_issue": "Yes", 
                "time_frame": "30 days, 9 months, 12 months"
            }, 
            {
                "measure": "All revascularization rate", 
                "safety_issue": "No", 
                "time_frame": "30 days, 9 months, 12 months"
            }, 
            {
                "description": "Q-wave and non-Q-wave", 
                "measure": "Myocardial infarction (MI) rate", 
                "safety_issue": "Yes", 
                "time_frame": "30 days, 9 months, 12 months"
            }, 
            {
                "measure": "Cardiac death rate", 
                "safety_issue": "Yes", 
                "time_frame": "30 days, 9 months, 12 months"
            }, 
            {
                "measure": "Non-cardiac death rate", 
                "safety_issue": "Yes", 
                "time_frame": "30 days. 9 months, 12 months"
            }, 
            {
                "measure": "All death rate", 
                "safety_issue": "Yes", 
                "time_frame": "30 days, 9 months, 12 months"
            }, 
            {
                "measure": "Cardiac death or MI rate", 
                "safety_issue": "Yes", 
                "time_frame": "30 days, 9 months, 12 months"
            }, 
            {
                "measure": "All death or MI rate", 
                "safety_issue": "Yes", 
                "time_frame": "30 days, 9 months, 12 months"
            }, 
            {
                "measure": "All death/MI/TVR rate", 
                "safety_issue": "Yes", 
                "time_frame": "30 days, 9 months, 12 months"
            }, 
            {
                "description": "by Academic Research Consortium [ARC] definitions", 
                "measure": "Stent thrombosis rates", 
                "safety_issue": "Yes", 
                "time_frame": "30 days, 9 months, 12 months"
            }, 
            {
                "description": "ischemic and hemorrhagic", 
                "measure": "Stroke rate", 
                "safety_issue": "Yes", 
                "time_frame": "30 days, 9 months, 12 months"
            }, 
            {
                "measure": "Longitudinal stent deformation rate assessed by an independent angiographic core laboratory", 
                "safety_issue": "No", 
                "time_frame": "30 days, 9 months, 12 months"
            }, 
            {
                "description": "Technical success is successful delivery and deployment of the study stent to the target vessel, without balloon rupture or stent embolization, and post-procedure diameter stenosis of <30% in 2 near-orthogonal projections with TIMI 3 flow in the target lesion, as visually assessed by the physician.", 
                "measure": "Technical success rate", 
                "safety_issue": "No", 
                "time_frame": "Participants will be followed for the duration of hospital stay, an expected average of 1 day."
            }, 
            {
                "description": "Clinical procedural success is post-procedure diameter stenosis <30% in 2 near-orthogonal projections with TIMI 3 flow in all target lesions, as visually assessed by the physician, without the occurrence of in-hospital MI, TVR, or cardiac death.", 
                "measure": "Clinical procedural success rate", 
                "safety_issue": "Yes", 
                "time_frame": "Participants will be followed for the duration of hospital stay, an expected average of 1 day."
            }, 
            {
                "description": "QCA will be done by an external Lab, but the angio used for the QCA is done during procedure.", 
                "measure": "In-stent and in-segment percent diameter stenosis (%DS) measured by QCA", 
                "safety_issue": "No", 
                "time_frame": "Participants will be followed for the duration of hospital stay, an expected average of 1 day."
            }, 
            {
                "description": "QCA will be done by an external Lab, but the angio used for the QCA is done during procedure.", 
                "measure": "In-stent and in-segment minimum lumen diameter (MLD) measured by QCA", 
                "safety_issue": "No", 
                "time_frame": "Participants will be followed for the duration of hospital stay, an expected average of 1 day."
            }, 
            {
                "description": "QCA will be done by an external Lab, but the angio used for the QCA is done during procedure.", 
                "measure": "In-stent and in-segment acute gain measured by QCA", 
                "safety_issue": "No", 
                "time_frame": "Participants will be followed for the duration of hospital stay, an expected average of 1 day."
            }, 
            {
                "description": "QCA will be done by an external Lab, but the angio used for the QCA is done during procedure.", 
                "measure": "Longitudinal stent deformation rate by QCA", 
                "safety_issue": "No", 
                "time_frame": "Participants will be followed for the duration of hospital stay, an expected average of 1 day."
            }, 
            {
                "description": "Measured by QCA", 
                "measure": "In-stent and in-segment %DS", 
                "safety_issue": "No", 
                "time_frame": "9 months"
            }, 
            {
                "description": "QCA", 
                "measure": "In-segment late loss", 
                "safety_issue": "No", 
                "time_frame": "9 months"
            }, 
            {
                "description": "QCA", 
                "measure": "In-stent and in-segment binary restenosis rate", 
                "safety_issue": "No", 
                "time_frame": "9 months"
            }, 
            {
                "description": "QCA", 
                "measure": "In-stent and in-segment MLD", 
                "safety_issue": "No", 
                "time_frame": "9 months"
            }, 
            {
                "description": "QCA", 
                "measure": "Stent fracture rate", 
                "safety_issue": "No", 
                "time_frame": "9 months"
            }, 
            {
                "description": "QCA", 
                "measure": "Longitudinal stent deformation rate", 
                "safety_issue": "No", 
                "time_frame": "9 months"
            }, 
            {
                "description": "IVUS", 
                "measure": "Incomplete apposition", 
                "safety_issue": "No", 
                "time_frame": "9 months"
            }, 
            {
                "description": "IVUS", 
                "measure": "Percent net volume obstruction", 
                "safety_issue": "No", 
                "time_frame": "9 months"
            }, 
            {
                "description": "IVUS", 
                "measure": "Stent, vessel and lumen area volumes", 
                "safety_issue": "No", 
                "time_frame": "9 months"
            }
        ], 
        "source": "Boston Scientific Corporation", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Beth Israel Deaconess Medical Center", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Medstar Research Institute", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Quintiles", 
                    "agency_class": "Industry"
                }, 
                {
                    "agency": "Medidata Solutions", 
                    "agency_class": "Industry"
                }
            ], 
            "lead_sponsor": {
                "agency": "Boston Scientific Corporation", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}